#ERS26: Beam says AATD base editing data hold up after one yearnews2026-09-08T08:30:35+00:00September 8th, 2026|Endpoints News|
Updated: Novartis sinks after second disastrous trial failure, this time of Avidity-acquired drugnews2026-09-08T08:24:44+00:00September 8th, 2026|Endpoints News|
Novartis’ Phase 3 pelacarsen study miss raises the stakes for Amgen, Lillynews2026-09-07T14:48:28+00:00September 7th, 2026|Endpoints News|
Updated: Novo Nordisk cans 2 more trials of IL-6 heart drug for futilitynews2026-09-07T07:53:43+00:00September 7th, 2026|Endpoints News|
AbbVie claims Phase 3 win for multiple myeloma drug etentamignews2026-09-03T14:50:40+00:00September 3rd, 2026|Endpoints News|
Summit, Akeso say ivonescimab clears OS bar in Phase 3 lung cancer trialnews2026-09-03T11:12:36+00:00September 3rd, 2026|Endpoints News|
Ultragenyx’s Angelman therapy fails Phase 3 trial in setback for company and patientsnews2026-09-03T01:35:17+00:00September 3rd, 2026|Endpoints News|
Novartis CAR-T deaths raise questions over acceptable autoimmune risknews2026-09-02T18:48:44+00:00September 2nd, 2026|Endpoints News|
Teva says gluten challenge study succeeds in celiac diseasenews2026-09-02T14:58:42+00:00September 2nd, 2026|Endpoints News|
ARPA-H awards $125M for manufacturing custom RNA therapies on demandnews2026-09-01T18:32:08+00:00September 1st, 2026|Endpoints News|
